Compare SCCO & PFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCCO | PFE |
|---|---|---|
| Founded | 1952 | 1849 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.3B | 141.6B |
| IPO Year | N/A | N/A |
| Metric | SCCO | PFE |
|---|---|---|
| Price | $157.82 | $25.31 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 10 | 10 |
| Target Price | ★ $122.56 | $27.40 |
| AVG Volume (30 Days) | 1.1M | ★ 46.9M |
| Earning Date | 02-11-2026 | 02-03-2026 |
| Dividend Yield | 2.23% | ★ 6.76% |
| EPS Growth | 25.54 | ★ 131.89 |
| EPS | ★ 4.67 | 1.73 |
| Revenue | $12,334,600,000.00 | ★ $62,785,000,000.00 |
| Revenue This Year | $13.43 | N/A |
| Revenue Next Year | $6.38 | N/A |
| P/E Ratio | $34.24 | ★ $14.73 |
| Revenue Growth | ★ 12.70 | 3.89 |
| 52 Week Low | $72.75 | $20.92 |
| 52 Week High | $161.59 | $27.69 |
| Indicator | SCCO | PFE |
|---|---|---|
| Relative Strength Index (RSI) | 67.19 | 49.20 |
| Support Level | $142.00 | $24.83 |
| Resistance Level | $161.59 | $26.01 |
| Average True Range (ATR) | 3.53 | 0.38 |
| MACD | 1.00 | -0.01 |
| Stochastic Oscillator | 81.99 | 32.34 |
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. It generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. The company's geographical segments are The Americas, Europe, and Asia.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.